Journal article
Retinal arteriolar narrowing and incidence of knee replacement for osteoarthritis: A prospective cohort study
SM Hussain, Y Wang, JE Shaw, DJ Magliano, TY Wong, AE Wluka, S Graves, RJ Tapp, FM Cicuttini
Osteoarthritis and Cartilage | ELSEVIER SCI LTD | Published : 2015
Abstract
Objectives: The role of the microcirculation in the pathogenesis of osteoarthritis (OA) remains unclear. This prospective cohort study examined the association between retinal vascular calibre and incidence of knee replacement for OA. Design: 1838 participants of the Australian Diabetes, Obesity and Lifestyle (AusDiab) Study had retinal vascular calibre measured using a nonmydriatic digital fundus camera in 1999-2000 and were aged ≥40 years at joint replacement data collection commencement. The incidence of knee replacement for OA during 2002-2011 was determined by linking cohort records to the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR). Results: 77 part..
View full abstractGrants
Awarded by Arthritis Australia
Funding Acknowledgements
For the Australian Diabetes, Obesity and Lifestyle (AusDiab) Study, funding support has been received from the National Health and Medical Research Council (NHMRC grant 233200), Australian Government Department of Health and Ageing, Abbott Australasia Pty Ltd, Alphapharm Pty Ltd, AstraZeneca, Bristol-Myers Squibb, City Health Centre-Diabetes Service-Canberra, Department of Health and Community Services - Northern Territory, Department of Health and Human Services - Tasmania, Department of Health - New South Wales, Department of Health - Western Australia, Department of Health - South Australia, Department of Human Services - Victoria, Diabetes Australia, Diabetes Australia Northern Territory, Eli Lilly Australia, Estate of the Late Edward Wilson, GlaxoSmithKline, Jack Brockhoff Foundation, Janssen-Cilag, Kidney Health Australia, Marian & FH Flack Trust, Menzies Research Institute, Merck Sharp & Dohme, Novartis Pharmaceuticals, Novo Nordisk Pharmaceuticals, Pfizer Pty Ltd, Pratt Foundation, Queensland Health, Roche Diagnostics Australia, Royal Prince Alfred Hospital, Sydney, Sanofi Aventis, Sanofi-synthelabo, and the Victorian Government's OIS Program.r The current linkage study is supported by Arthritis Australia. SMH is the recipient of Endevour IPRS and APA scholarship from the Australian government and Faculty Excellence Scholarship from Monash University. YW is the recipient of an NHMRC Career Development Fellowship (Clinical level 1, #1065464). JES is supported by a National Health and Medical Research Council Research Fellowship. AEW is supported by Monash University, Senior Postdoctoral Fellowship, NHMRC Career Development Fellowship (Clinical level 2, #1063574).